Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of respiratory tract infections with ciprofloxacin.

Literature DB >> 3804902

Treatment of respiratory tract infections with ciprofloxacin.

Abstract

The efficacy and safety of ciprofloxacin in an oral dose of 750 mg twice daily, in the treatment of respiratory infections was studied in 129 patients. Ciprofloxacin showed broad in-vitro antibacterial activity and was highly effective in both Gram-negative and Gram-positive infections with a clinical cure rate of 96%. The major side effect was an interaction with theophylline particularly in the elderly patients.

Entities: Chemical Disease Species

Mesh：

Substances：
Ciprofloxacin

Year: 1986 PMID： 3804902 DOI： 10.1093/jac/18.supplement_d.139

Source DB: PubMed Journal: J Antimicrob Chemother ISSN： 0305-7453 Impact factor: 5.790

Keyword Cloud
Cited

11 in total

1. A clinically significant interaction between ciprofloxacin and theophylline.

Authors: A H Thomson; G D Thomson; M Hepburn; B Whiting
Journal: Eur J Clin Pharmacol Date: 1987 Impact factor: 2.953

Review 2. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors: J H Paton; D S Reeves
Journal: Drugs Date: 1988-08 Impact factor: 9.546

Review 3. Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors: G Maschmeyer
Journal: Drugs Date: 1993 Impact factor: 9.546

4. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors: S K Spangler; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1992-04 Impact factor: 5.191

5. Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.

Authors: J Gisby; B J Wightman; A S Beale
Journal: Antimicrob Agents Chemother Date: 1991-05 Impact factor: 5.191

Review 6. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors: J P Thys; F Jacobs; B Byl
Journal: Eur J Clin Microbiol Infect Dis Date: 1991-04 Impact factor: 3.267

Treatment of respiratory tract infections with ciprofloxacin.

1. A clinically significant interaction between ciprofloxacin and theophylline.

Review 2. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Review 3. Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

4. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

5. Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.

Review 6. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

7. Co-administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction.

8. Rufloxacin once daily in acute exacerbations of chronic bronchitis.

9. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong.

Review 10. Fluoroquinolone antimicrobial agents.